Don’t ask for the determination of serum biomarkers like CEA, CA-125, HE4, CA-15.3, a-fetoprotein or CA-19.9 for the diagnosis of neoplastic disease in asymptomatic patients.
The diagnostic sensitivity and specificity of these biomarkers are not sufficient to allow their use (diagnosis, screening, case-finding) in a population with a low prevalence of neoplastic diseases. Their use is recommended for the monitoring of the neoplasms that express the specific biomarker (Colon – rectal: CEA; Ovarian: CA-125 and / or HE4; Brest cancer: CA-15.3; Hepatocarcinoma: a-fetoprotein; Pancreatic: CA-19.9).
1. Sturgeon CM, Diamandis E Eds. LMPG. Use of Tumor Markers of Testicular, Prostate, Colorectal, Breast, and Ovarian Cancer. NACB 2009 https://www.aacc.org/~/media/practice-guidelines/major-tumor-markers/tumormarkersmajor10.pdf?la=en
2. Esposito E, Dorizzi RM. La risposta dei marcatori tumorali (indicatori di neoplasia). RIMeL/IJLaM 2005; 1(suppl): 82-7.
Attention. Please note that these items are provided only for information and are not intended as a substitute for consultation with a clinician. Patients with any specific questions about the items on this list or their individual situation should consult their clinician.